Difference between revisions of "Tislelizumab (Baizean)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tislelizumab NCI Drug Dictionary]: A monoclonal antibody directed against th...") |
|||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Esophageal squamous cell carcinoma]]=== | ===[[Esophageal squamous cell carcinoma]]=== | ||
| − | # ''' | + | # '''RATIONALE 302:''' NCT03430843 |
==Also known as== | ==Also known as== | ||
Revision as of 18:27, 5 June 2021
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Preliminary data
Esophageal squamous cell carcinoma
- RATIONALE 302: NCT03430843
Also known as
- Code name: BGB-A317